MARIPOSA-2
10 evidence topics · 3 sources
Objective
Location and study date
Geographic scope
Study design
Eligibility criteria
Eligible EGFR alterations
Treatment
Randomized treatment groups
| Group | Quoted regimen |
|---|---|
| Combination with lazertinib | “amivantamab-lazertinib-chemotherapy” |
| Control | “chemotherapy” |
| Combination without lazertinib | “amivantamab-chemotherapy” |
Chemotherapy backbone
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Dual primary comparison endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Predominant adverse-event categories
Study limitations
Summary
This trial compares amivantamab-based combinations with chemotherapy, not with ivonescimab. Its PFS results therefore cannot establish the relative efficacy of amivantamab and ivonescimab. Toxicities span hematologic, EGFR-related, and MET-related categories; a PFS comparison alone does not summarize the full benefit-risk balance.